<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00578526</url>
  </required_header>
  <id_info>
    <org_study_id>SPRUCE02</org_study_id>
    <nct_id>NCT00578526</nct_id>
  </id_info>
  <brief_title>SU011248 for Platinum-Refractory Urothelial Cancer Evaluation Trial</brief_title>
  <acronym>SPRUCE</acronym>
  <official_title>A Randomized, Placebo-controlled Phase II Study to Compare the Efficacy and Safety of SU011248 Versus Placebo in Patients With Advanced Urothelial Transitional Cell Carcinoma Who Have Failed or Are Intolerant to Cisplatin-based Chemotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AHS Cancer Control Alberta</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>AHS Cancer Control Alberta</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to find out if SU011248 works and if it is safe in patients with&#xD;
      advanced transitional cell carcinoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study objectives include the determination of the antitumor effect of SU011248 in&#xD;
      patients with urothelial transitional cell carcinoma and to also determine the toxicities and&#xD;
      tolerability of SU011248 in patients with urothelial transitional cell carcinoma who have&#xD;
      failed or are intolerant to cisplatin-based chemotherapy.&#xD;
&#xD;
      The primary endpoint of the study is to compare progression free survival at 4 months in&#xD;
      patients who received SU011248 plus BSC versus patients who received placebo plus BSC&#xD;
&#xD;
      The secondary endpoint is to compare the objective response rate and duration of response in&#xD;
      patients who received SU011248 plus BSC versus patients who received placebo plus BSC, to&#xD;
      describe the QOL and safety profile of SU011248 when compared to placebo and to describe the&#xD;
      overall survival in patients who received SU011248 plus BSC versus patients who received&#xD;
      placebo plus BSC&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2008</start_date>
  <completion_date type="Actual">July 16, 2014</completion_date>
  <primary_completion_date type="Actual">July 16, 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression Free Survival</measure>
    <time_frame>4 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>objective response rate</measure>
    <time_frame>Study Duration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>duration of response</measure>
    <time_frame>study duration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in health-related quality of life</measure>
    <time_frame>Study Duration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants that develop an adverse event to treatment.</measure>
    <time_frame>Study Duration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>Study Duration</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">64</enrollment>
  <condition>Urothelial Cancer</condition>
  <condition>Bladder Cancer</condition>
  <condition>Adult</condition>
  <arm_group>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>SU011248 - 4 weeks on followed by 2 weeks rest period every 6 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>1 50 mg capsule OD PO for 4 weeks with 2 week rest until disease progression. Any patient with disease progression will be unblinded and patients on the placebo arm may then be considered for the open label Sutent treatment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SU011248</intervention_name>
    <description>50 mg capsule OD PO for 28 days followed by 14 days of rest until tumor progression</description>
    <arm_group_label>Arm 1</arm_group_label>
    <other_name>Sutent, Sunitinib</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>50 mg capsule OD PO for 28 days then 14 days rest until disease progression</description>
    <arm_group_label>Arm 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically/cytologically proven inoperable, metastatic or recurrent transitional&#xD;
             cell carcinoma of the urothelial tract&#xD;
&#xD;
          -  Mixed histology with predominant TCC allowed.&#xD;
&#xD;
          -  Failed, intolerant or ineligible for cisplatin based chemo&#xD;
&#xD;
          -  Measurable Disease (RECIST)Not previously irradiated.&#xD;
&#xD;
          -  Recovered from previous acute treatment to grade 1(CTCAE Vers. 3.0)&#xD;
&#xD;
          -  No weight loss &gt;/- 10% within 28 days of day 0&#xD;
&#xD;
          -  Adequate Organ Function&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Adenocarcinoma, squamous carcinoma or other histology without any components of&#xD;
             transitional carcinoma.&#xD;
&#xD;
          -  Small cell histology&#xD;
&#xD;
          -  More than one previous systemic chemo&#xD;
&#xD;
          -  Excised metastases without remaining measureable disease&#xD;
&#xD;
          -  Prior therapy with angiogenesis inhibitors&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tina Cheng, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>Tom Baker Cancer Centre</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Tom Baker Cancer Centre</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2N 4N2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cross Cancer Institute</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G 1Z2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>British Columbia Cancer Agency - Vancouver Centre</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z 4E6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Juravinski Cancer Centre</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8V 5C2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>London Health Sciences Centre</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>T6A 4L6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>August 2018</verification_date>
  <study_first_submitted>December 19, 2007</study_first_submitted>
  <study_first_submitted_qc>December 20, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 21, 2007</study_first_posted>
  <last_update_submitted>August 20, 2018</last_update_submitted>
  <last_update_submitted_qc>August 20, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">August 22, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>AHS Cancer Control Alberta</investigator_affiliation>
    <investigator_full_name>Tina Cheng</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>urothelial cancer</keyword>
  <keyword>targeted therapy</keyword>
  <keyword>antiangiogenesis therapy</keyword>
  <keyword>SU011248</keyword>
  <keyword>clinical trial</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Bladder Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sunitinib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

